Study launches of novel imaging radiopharmaceutical in NMIBC

The investigational imaging radiopharmaceutical TLX250-CDx targets the receptor carbonic anhydrase IX (CA9), which is overexpressed in urologic cancers.

Read the full article here

Related Articles